My question for the shareholders meeting

[biopearl123]

Hi Aron, hope you are well. It appears things are in full swing at Geron. This year I have only one (!) question for consideration at the annual shareholders meeting: As we as shareholders try to understand the implications of “disease modification”, does Geron see data developing to support a reduction in leukemia transformation and life extension in the LR MDS population? This appeared not to be the case in the COMMANDS study which suggested similar death rates in both study arms. Best wishes for continued success. Sincerely, XXXXX, M.D., moderator of “Imetelchat” board.

If anyone wants to submit questions please do. As to the doubling of share numbers, I think most companies will avoid discussions of internal decisions re avoiding hostile take over strategies. But you can try. Best Wishes, bp